Proteomic profiling platforms head to head: Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods.
Proteomic profiling platforms head to head: Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods.
复制标题
DOI：
10.1126/sciadv.abm5164
复制
发表时间：
2022-08-19
期刊：
影响因子：
13.6
通讯作者：
中科院分区：
文献类型：
--
作者：
使用基于抗体或适体的亲和试剂的高通量蛋白质组学分析越来越多地用于人类研究。然而，缺乏对这些平台的相对优势和劣势的直接分析。我们评估了SomaScan1.3K的发现，（N = 1301试剂），SomaScan5K平台（N = 4979试剂）和Olink Explore在杰克逊心脏研究的568名成年人和HERITAGE家族研究的219名参与者中，在四个性能领域使用（N = 1472种试剂）分析技术：精确度、准确度、分析广度和利用详细临床表型和遗传数据的表型关联。在这些研究中，我们显示了支持Olink平台更可靠的蛋白质靶点特异性和更高数量的表型关联的证据，而索马平台受益于更高的测量精度和整个蛋白质组的分析广度。两个高通量蛋白质组学平台突出了精度，准确性，广度和表型关联的差异。
High-throughput proteomic profiling using antibody or aptamer-based affinity reagents is used increasingly in human studies. However, direct analyses to address the relative strengths and weaknesses of these platforms are lacking. We assessed findings from the SomaScan1.3K (N = 1301 reagents), the SomaScan5K platform (N = 4979 reagents), and the Olink Explore (N = 1472 reagents) profiling techniques in 568 adults from the Jackson Heart Study and 219 participants in the HERITAGE Family Study across four performance domains: precision, accuracy, analytic breadth, and phenotypic associations leveraging detailed clinical phenotyping and genetic data. Across these studies, we show evidence supporting more reliable protein target specificity and a higher number of phenotypic associations for the Olink platform, while the Soma platforms benefit from greater measurement precision and analytic breadth across the proteome. Two high-throughput proteomics platforms highlight differences in precision, accuracy, breadth, and phenotypic associations.
登录
查看更多内容
影响因子：
4.6
作者：
Candia J;Cheung F;Kotliarov Y;Fantoni G;Sellers B;Griesman T;Huang J;Stuccio S;Zingone A;Ryan BM;Tsang JS;Biancotto A
通讯作者：
Biancotto A
影响因子：
3.7
作者：
Gold L;Ayers D;Bertino J;Bock C;Bock A;Brody EN;Carter J;Dalby AB;Eaton BE;Fitzwater T;Flather D;Forbes A;Foreman T;Fowler C;Gawande B;Goss M;Gunn M;Gupta S;Halladay D;Heil J;Heilig J;Hicke B;Husar G;Janjic N;Jarvis T;Jennings S;Katilius E;Keeney TR;Kim N;Koch TH;Kraemer S;Kroiss L;Le N;Levine D;Lindsey W;Lollo B;Mayfield W;Mehan M;Mehler R;Nelson SK;Nelson M;Nieuwlandt D;Nikrad M;Ochsner U;Ostroff RM;Otis M;Parker T;Pietrasiewicz S;Resnicow DI;Rohloff J;Sanders G;Sattin S;Schneider D;Singer B;Stanton M;Sterkel A;Stewart A;Stratford S;Vaught JD;Vrkljan M;Walker JJ;Watrobka M;Waugh S;Weiss A;Wilcox SK;Wolfson A;Wolk SK;Zhang C;Zichi D
通讯作者：
Zichi D
影响因子：
2.1
作者：
Conomos MP;Miller MB;Thornton TA
通讯作者：
Thornton TA
DNA甲基化介导了1型糖尿病中HBA1C相关并发症的发展。
影响因子：
20.8
作者：
Chen Z;Miao F;Braffett BH;Lachin JM;Zhang L;Wu X;Roshandel D;Carless M;Li XA;Tompkins JD;Kaddis JS;Riggs AD;Paterson AD;DCCT/EDIC Study Group;Natarajan R
通讯作者：
Natarajan R
影响因子：
5.8
作者：
Kamat, Mihir A.;Blackshaw, James A.;Staley, James R.
通讯作者：
Staley, James R.